International Urology and Nephrology
Latest Publications


TOTAL DOCUMENTS

6801
(FIVE YEARS 1007)

H-INDEX

46
(FIVE YEARS 8)

Published By Springer-Verlag

1573-2584, 0301-1623

Author(s):  
Limy Wong ◽  
Annette B. Kent ◽  
Darren Lee ◽  
Matthew A. Roberts ◽  
Lawrence P. McMahon

Author(s):  
Michael E. Chua ◽  
Justin Jin Kyu Kim ◽  
Jessica M. Ming ◽  
Mark Jason De Jesus ◽  
Manuel C. See ◽  
...  

Author(s):  
Yi-Jia Jiang ◽  
Xiu-Ming Xi ◽  
Hui-Miao Jia ◽  
Xi Zheng ◽  
Mei-Ping Wang ◽  
...  

Abstract Purpose This study aimed to evaluate the attributable mortality of new-onset acute kidney injury (AKI). Methods The data in the present study were derived from a multi-center, prospective cohort study in China that was performed at 18 Chinese ICUs. A propensity-matched analysis was performed between matched patients with and without AKI selected from all eligible patients to estimate the attributable mortality of new-onset AKI. Results A total of 2872 critically ill adult patients were eligible. The incidence of new-onset AKI was 29.1% (n = 837). After propensity score matching, 788 patients with AKI were matched 1:1 with 788 controls (patients without AKI). Thirty-day mortality was significantly higher among the patients with AKI than among their matched controls (25.5% versus 17.4%, p < 0.001). Subgroup analysis in terms of AKI classification showed that there was no significant difference (p = 0.509) in 30-day mortality between patients with stage 1 AKI and their matched controls. The attributable mortality values of stage 2 and stage 3 AKI were 12.4% [95% confidence interval (CI) 2.6–21.8%, p = 0.013] and 16.1% (95% CI 8.2–23.8%, p < 0.001), respectively. The attributable mortality of persistent AKI was 15.7% (95% CI 8.8–22.4%, p = 0.001), while no observable difference in 30-day mortality was identified between transient AKI patients and their matched non-AKI controls (p = 0.229). Conclusion The absolute excess 30-day mortality that is statistically attributable to new-onset AKI is substantial (8.1%) among general ICU patients. However, neither stage 1 AKI nor transient AKI increases 30-day mortality.


Author(s):  
Brett J. Friedman ◽  
Jennifer Nguyen ◽  
Annah Vollstedt ◽  
Mireya Diaz ◽  
Ly Hoang Roberts ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document